MRNA Stock Risk & Deep Value Analysis
Moderna Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About MRNA Stock
We analyzed Moderna Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MRNA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is MRNA Stock?
Overall Risk
Aggressive
Financial Risk
Low
Market Risk
Medium
Competitive Risk
High
Execution Risk
Medium
Regulatory Risk
Medium
What Are the Red Flags for MRNA?
- ⚠
Clinical trial failures or significant delays for Flu/CMV vaccines
- ⚠
Slower-than-expected mRESVIA market penetration due to competitive pressure
- ⚠
Intensified competition in the mRNA space from BioNTech, Pfizer, or new entrants
- ⚠
Unfavorable regulatory decisions or heightened scrutiny
Unlock MRNA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Moderna Inc (MRNA) Do?
Market Cap
$12.73B
Sector
Healthcare
Industry
Biotechnology
Employees
5,800
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Visit Moderna Inc WebsiteIs MRNA Stock Undervalued?
Unlock the full AI analysis for MRNA
Get the complete DVR score, risk analysis, and more
Does MRNA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Moderna's moat is durable due to its leadership in mRNA technology, extensive patent thicket, and operational scale. As new products are approved, the platform's value and market entrenchment grow, making it harder for competitors to catch up across multiple indications.
Moat Erosion Risks
- •Patent challenges and expiry, allowing generic competition in the long term
- •Breakthroughs in alternative technologies that could offer superior solutions
- •Intense competition from other large pharmaceutical companies investing heavily in mRNA research and development
MRNA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive MRNA Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report & 2026 Guidance (Late February / Early March 2026)
- •Updates on mRESVIA (RSV vaccine) commercial uptake and market penetration
- •Phase 3 data readout for mRNA-1345 (Flu vaccine) (Expected mid-2026)
Medium-Term (6-18 months)
- •Potential Biologics License Application (BLA) submission for mRNA-1345 (Flu vaccine) (Late 2026 / Early 2027)
- •Phase 3 data readout for mRNA-1647 (CMV vaccine) (Expected Late 2026 / Early 2027)
- •Further progress and initial readouts from oncology and rare disease pipeline programs
Long-Term (18+ months)
- •Multiple mRNA vaccine/therapeutic approvals beyond infectious diseases (3-5 years)
- •Establishment of mRNA as a foundational modality for various therapeutic areas
- •Disruption of traditional vaccine and immunology markets with superior efficacy/safety profiles
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MRNA?
- ✓
Faster-than-expected mRESVIA market share capture
- ✓
Positive Phase 3 readouts for Flu and CMV vaccines
- ✓
Improvement in overall R&D efficiency and pipeline progression to key milestones
Bull Case Analysis
See what could go right with Premium
Compare MRNA to Similar Stocks
See how Moderna Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MRNA (Moderna Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
